Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The protein kinase D (PKD) family consists of three serine/threonine protein kinases:
PKC
mu/PKD, PKD2, and
PKC
nu/
PKD3
. While PKD has been the focus of most studies to date, no information is available on the intracellular distribution of PKD2. Consequently, we examined the mechanism that regulates its intracellular distribution in human pancreatic carcinoma Panc-1 cells. Analysis of the intracellular steady-state distribution of fluorescent-tagged PKD2 in unstimulated cells indicated that this kinase is predominantly cytoplasmic. Cell stimulation with the G protein-coupled receptor agonist neurotensin induced a rapid and reversible plasma membrane translocation of PKD2 by a mechanism that requires
PKC
activity. In contrast to the other PKD isoenzymes, PKD2 activation did not induce its redistribution from the cytoplasm to the nucleus. Thus, this study demonstrates that the regulation of the distribution of PKD2 is distinct from other PKD isoenzymes, and suggests that the differential spatio-temporal localization of these signaling molecules regulates their specific signaling properties.
...
PMID:Intracellular redistribution of protein kinase D2 in response to G-protein-coupled receptor agonists. 1264 43
The protein kinase D (PKD) family consists of three serine/threonine kinases:
PKC
micro/PKD, PKD2, and PKCnu/
PKD3
. Whereas PKD has been the focus of most studies, virtually nothing is known about the effect of G protein-coupled receptor agonists (GPCR) on the regulatory properties and intracellular distribution of
PKD3
. Consequently, we examined the mechanism that mediates its activation and intracellular distribution. GPCR agonists induced a rapid activation of
PKD3
by a
protein kinase C
(
PKC
)-dependent pathway that leads to the phosphorylation of the activation loop of
PKD3
. Comparison of the steady-state distribution of endogenous or tagged
PKD3
versus PKD and PKD2 in unstimulated cells indicated that whereas PKD and PKD2 are predominantly cytoplasmic,
PKD3
is present both in the nucleus and cytoplasm. This distribution of
PKD3
results from its continuous shuttling between both compartments by a mechanism that requires a nuclear import receptor and a competent CRM1-nuclear export pathway. Cell stimulation with the GPCR agonist neurotensin induced a rapid and reversible plasma membrane translocation of
PKD3
that is
PKC
-dependent. Interestingly, the nuclear accumulation of
PKD3
can be dramatically enhanced in response to its activation. Thus, this study demonstrates that the intracellular distribution of PKD isoenzymes are distinct, and suggests that their signaling properties are regulated by differential localization.
...
PMID:Protein kinase C nu/protein kinase D3 nuclear localization, catalytic activation, and intracellular redistribution in response to G protein-coupled receptor agonists. 1267 44
Protein kinase C (PKC) and protein kinase D (PKD) coordinate and regulate many fundamental cellular processes. In this study, we evaluate the role of classic and novel PKC (c/
nPKC
) and PKD in glucose transport in L6 myotubes. c/
nPKC
is either activated by short-term phorbol 12-myristate 13-acetate (PMA) treatment or down-regulated by prolonged PMA treatment at a high dose in L6 myotubes. Our results indicate that PMA treatments have little impact on basal and insulin-stimulated glucose uptake and insulin-induced Akt activation. In contrast, the PKC inhibitors Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c] carbazole], Go6983 [2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)maleimide], GF 109203X [bisindolylmaleimide I; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(1H-indol-3-yl)maleimide], and Ro 31-8220 [bisindolylmaleimide IX; 2-{1-[3-(amidinothio)propyl]-1H-indol3-yl}-3-(1-methylindol-3-yl)maleimide] block basal and insulin-stimulated glucose uptake, and their inhibitory effects persist upon down-regulation of c/
nPKC
by PMA, implying the presence of PKC-independent effectors in mediating their inhibition of glucose uptake. Go6976, the potent cPKC inhibitor that also effectively inhibits PKD, dose-dependently blocks basal glucose uptake in L6 myotubes, whereas Go6983, the nonselective PKC inhibitor that is ineffective for PKD, has little effect on basal glucose uptake, implying the involvement of PKD in this process. Most prominently, adenoviral gene expression of a dominant-negative PKD isoform,
PKD3
, primarily inhibits basal glucose uptake and, to a lesser extent, insulin-stimulated glucose uptake, whereas overexpression of wild-type
PKD3
significantly enhances basal glucose uptake. Moreover, expression of a
PKD3
-targeted siRNA significantly inhibits basal glucose uptake. Taken together, our results indicate that PKD, specifically
PKD3
, directly contributes to insulin-independent basal glucose uptake in L6 skeletal muscle cells.
...
PMID:Protein kinase C-independent effects of protein kinase D3 in glucose transport in L6 myotubes. 1549 5
Protein kinase D3 is a novel member of the serine/threonine kinase family PKD. The regulatory region of PKD contains a tandem repeat of C1 domains designated C1a and C1b that bind diacylglycerol and phorbol esters, and are important membrane targeting modules. Here, we investigate the activities of individual C1 domains of
PKD3
and their roles in phorbol ester-induced plasma membrane translocation of
PKD3
. Truncated C1a of
PKD3
binds [(3)H]phorbol 12, 13-dibutyrate with high affinity, but no binding activity is detected for C1b. Meanwhile, mutations in C1a of truncated C1ab of
PKD3
lead to the loss of binding affinity, while these mutations in C1b have little impact, indicating that C1a is responsible for most of the phorbol ester-binding activities of
PKD3
. C1a and C1b of the GFP-tagged full length
PKD3
are then mutated to assess their roles in phorbol ester-induced plasma membrane translocation in intact cells. At low concentration of phorbol 12-myristate 13-acetate (PMA), the plasma membrane translocations of the C1a and C1ab mutants are significantly impaired, reflecting an important role of C1a in this process. However, at higher PMA concentrations, all C1 mutants exhibit increased rates of translocation as compared to that of wild-type
PKD3
, which parallel their enhanced activation by PMA, implying that
PKD3
kinase activity affects membrane targeting. In line with this, a constitutive active
PKD3
-GFP translocates similarly as wild-type
PKD3
, while a kinase-inactive
PKD3
shows little translocation up to 2 muM PMA. In addition, RO 31-8220, a potent
PKC
inhibitor that blocks PMA-induced
PKD3
activation in vivo, significantly attenuates the plasma membrane translocation of wild-type
PKD3
at different doses of PMA. Taken together, our results indicate that both C1a and the kinase activity of
PKD3
are necessary for the phorbol ester-induced plasma membrane translocation of
PKD3
.
PKC
, by directly activating
PKD3
, regulates its plasma membrane localization in intact cells.
...
PMID:Individual C1 domains of PKD3 in phorbol ester-induced plasma membrane translocation of PKD3 in intact cells. 1592 50
PKD is the founding member of a novel protein kinase family that also includes PKD2 and
PKD3
. PKD has been the focus of most studies up to date, but little is known about the mechanisms that mediate
PKD3
activation. Here, we show that addition of aluminum fluoride to COS-7 cells cotransfected with
PKD3
and Galpha13 or Galpha12 induced
PKD3
activation, which was associated with a transient plasma membrane translocation of cytosolic
PKD3
. Treatment with Clostridium difficile toxin B blocked
PKD3
activation induced by either bombesin or by aluminum fluoride-stimulated Galpha12/13 but did not affect Galphaq-induced
PKD3
activation. Furthermore,
PKD3
immunoprecipitated from cells cotransfected with a constitutively active Rac (RacV12) exhibited a marked increase in
PKD3
basal catalytic activity. In contrast, cotransfection with active Rho (RhoQ63L), Cdc42 (Cdc42Q61L), or Ras (RasV12) did not promote
PKD3
activation. Expression of either COOH-terminal dominant-negative fragment of Galpha13 or dominant negative Rac (Rac N17) attenuated bombesin-induced
PKD3
activation. Treatment with
protein kinase C
(
PKC
) inhibitors prevented the increase in
PKD3
activity induced by RacV12 and aluminum fluoride-stimulated Galpha12/13. The catalytic activation of
PKD3
in response to RacV12, alpha12/13 signaling or bombesin correlated with Ser-731/Ser-735 phosphorylation in the activation loop of this enzyme. Our results indicate that Galpha12/13 and Rac are important components in the signal transduction pathways that mediate bombesin receptor-induced
PKD3
activation.
...
PMID:Activation of protein kinase D3 by signaling through Rac and the alpha subunits of the heterotrimeric G proteins G12 and G13. 1619 87
Protein kinase D localizes in the Golgi and regulates protein transport from the Golgi to the plasma membrane. In the present study, we found that
PKD3
, a novel member of the PKD family, and its fluorescent protein fusions localized in the Golgi and in the vesicular structures that are in part marked by endosome markers. Fluorescent recovery after photobleaching (FRAP) showed that the
PKD3
-associated vesicular structures were constantly forming and dissolving, reflecting active subcellular structures. FRAP on plasma membrane-located
PKD3
indicated a slower recovery of
PKD3
fluorescent signal compared to those of
PKC
isoforms, implying a different targeting mechanism at the plasma membrane. VAMP2, the vesicle-localized v-SNARE, was later identified as a novel binding partner of
PKD3
through yeast two-hybrid screening.
PKD3
directly interacted with VAMP2 in vitro and in vivo, and colocalized in part with VAMP2 vesicles in cells.
PKD3
did not phosphorylate VAMP-GFP and the purified GST-VAMP2 protein in in vitro phosphorylation assays. Rather,
PKD3
was found to promote the recruitment of VAMP2 vesicles to the plasma membrane in response to PMA, while the kinase dead
PKD3
abolished this effect. Thus, the kinase activity of
PKD3
was required for PMA-induced plasma membrane trafficking of VAMP2. In summary, our findings suggest that
PKD3
localizes to vesicular structures that are part of the endocytic compartment. The vesicular distribution may be attributed in part to the direct interaction between
PKD3
and vesicle-associated membrane protein VAMP2, through which
PKD3
may regulate VAMP2 vesicle trafficking by facilitating its recruitment to the target membrane.
...
PMID:Protein kinase D 3 is localized in vesicular structures and interacts with vesicle-associated membrane protein 2. 1719 67
Tachykinins, acting through NK(3) receptors (NK(3)R), contribute to excitatory transmission to intrinsic primary afferent neurons (IPANs) of the small intestine. Although this transmission is dependent on
protein kinase C
(
PKC
), its maintenance could depend on protein kinase D (PKD), a downstream target of
PKC
. Here we show that PKD1/2-immunoreactivity occurred exclusively in IPANs of the guinea pig ileum, demonstrated by double staining with the IPAN marker NeuN.
PKCepsilon
was also colocalized with PKD1/2 in IPANs.
PKCepsilon
and PKD1/2 trafficking was studied in enteric neurons within whole mounts of the ileal wall. In untreated preparations,
PKCepsilon
and PKD1/2 were cytosolic and no signal for activated (phosphorylated) PKD was detected. The NK(3)R agonist senktide evoked a transient translocation of
PKCepsilon
and PKD1/2 from the cytosol to the plasma membrane and induced PKD1/2 phosphorylation at the plasma membrane.
PKCepsilon
translocation was maximal at 10 s and returned to the cytosol within 2 min. Phosphorylated-PKD1/2 was detected at the plasma membrane within 15 s and translocated to the cytosol by 2 min, where it remained active up to 30 min after NK(3)R stimulation. PKD1/2 activation was reduced by a
PKCepsilon
inhibitor and prevented by NK(3)R inhibition. NK(3)R-mediated
PKCepsilon
and PKD activation was confirmed in HEK293 cells transiently expressing NK(3)R and green fluorescent protein-tagged
PKCepsilon
, PKD1, PKD2, or
PKD3
. Senktide caused membrane translocation and activation of kinases within 30 s. After 15 min, phosphorylated PKD had returned to the cytosol. PKD activation was confirmed through Western blotting. Thus stimulation of NK(3)R activates
PKCepsilon
and PKD in sequence, and sequential activation of these kinases may account for rapid and prolonged modulation of IPAN function.
...
PMID:Stimulation of the neurokinin 3 receptor activates protein kinase C epsilon and protein kinase D in enteric neurons. 1830 56
Protein kinase D (PKD) is a family of novel diacylglycerol/phorbol ester targets that regulate many important cellular functions including cell growth and survival. We now provide experimental evidence to indicate that
PKD3
contributes to prostate cancer cell growth and survival. Expression of
PKD3
as well as PKD1 was significantly higher in human prostate tumors compared with normal tissues as revealed by immunohistochemistry. Moreover,
PKD3
exhibited a marked increase in nuclear localization in tumor tissues, which correlated with tumor grade. Isoforms of PKD were differentially expressed and localized between normal and human prostate cancer cells. Increased protein expression and nuclear accumulation of
PKD3
were observed in the more aggressive androgen-independent PC3 and DU145 cells compared with the less aggressive androgen-dependent LNCaP cells. Overexpression of wild-type
PKD3
in LNCaP cells blocked phorbol 12-myristate 13-acetate (PMA)-induced apoptosis in association with inhibition of PMA-induced down-regulation of Akt activity, and prolonged extracellular signal-regulated kinase (ERK)1/2 activation. Overexpression of wild-type
PKD3
also promoted S phase entry, whereas depletion of endogenous
PKD3
resulted in G(0)-G(1) phase cell cycle arrest and inhibition of PC3 cell proliferation. In PC3 and DU145 cells,
PKCepsilon
regulated
PKD3
kinase activity and nuclear localization. Moreover, ectopical expression of
PKD3
increased, whereas depletion of endogenous
PKD3
reduced basal Akt and ERK1/2 activities. Further analysis showed that up-regulation of Akt activity induced by
PKD3
required phosphatidylinositol-3-OH kinase and p38. In summary, our data indicate that
PKD3
contributes to growth and survival of prostate cancer cells and may represent a novel therapeutic target for prostate cancer.
...
PMID:Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. 1848 69
The protein kinase D (PKD) family consists of three serine/threonine protein kinases involved in the regulation of fundamental biological processes in response to their activation and intracellular redistribution. Although a substantial amount of information is available describing the mechanisms regulating the activation and intracellular distribution of the PKD isozymes during interphase, nothing is known of their activation status, localization and role during mitosis. The results presented in this study indicate that during mitosis,
PKD3
and PKD are phosphorylated at Ser(731) and Ser(744) within their activation loop by a mechanism that requires
protein kinase C
. Mitosis-associated
PKD3
Ser(731) and PKD Ser(744) phosphorylation is related to the catalytic activation of these kinases as evidenced by in vivo phosphorylation of histone deacetylase 5, a substrate of PKD and
PKD3
. Activation loop-phosphorylated
PKD3
and PKD, as well as PKD2, associate with centrosomes, spindles and midbody suggesting that these activated kinases establish dynamic interactions with the mitotic apparatus. Thus, this study reveals a connection between the PKD isozymes and cell division, suggesting a novel role for this family of serine/threonine kinases.
...
PMID:Protein kinase D isozymes activation and localization during mitosis. 1869 97
The protein kinase D (PKD) family of serine/threonine kinases, which can be activated by gastrointestinal hormones, consists of three distinct isoforms that modulate a variety of cellular processes including intracellular protein transport as well as constitutive and regulated secretion. Although isoform-specific functions have been identified in a variety of cell lines, the expression and function of PKD isoforms in normal, differentiated secretory tissues is unknown. Here, we demonstrate that PKD isoforms are differentially expressed in the exocrine and endocrine cells of the pancreas. Specifically,
PKD3
is the predominant isoform expressed in exocrine cells of the mouse and human pancreas, whereas PKD1 and PKD2 are more abundantly expressed in the pancreatic islets. Within isolated mouse pancreatic acinar cells,
PKD3
undergoes rapid membrane translocation, trans-activating phosphorylation, and kinase activation after gastrointestinal hormone or cholinergic stimulation. PKD phosphorylation in pancreatic acinar cells occurs viaaCa2+-independent, diacylglycerol- and
protein kinase C
-dependent mechanism. PKD phosphorylation can also be induced by physiologic concentrations of secretagogues and by in vivo stimulation of the pancreas. Furthermore, activation of
PKD3
potentiates MEK/ERK/RSK (RSK, ribosomal S6 kinase) signaling and significantly enhances cholecystokinin-mediated pancreatic amylase secretion. These findings reveal a novel distinction between the exocrine and endocrine cells of the pancreas and further identify
PKD3
as a signaling molecule that promotes hormone-stimulated amylase secretion.
...
PMID:PKD3 is the predominant protein kinase D isoform in mouse exocrine pancreas and promotes hormone-induced amylase secretion. 1902 87
1
2
Next >>